Spots Global Cancer Trial Database for FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Official Title: Early Prediction of Clinical Response to Chemotherapy With FLT-PET

Study ID: NCT00880074

Conditions

Malignant Neoplasm

Interventions

Fluorothymidine F-18

Laboratory Biomarker Analysis

Positron Emission Tomography

Study Description

Brief Summary: This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

Detailed Description: PRIMARY OBJECTIVES: I. To determine if concurrent treatment with temsirolimus and bevacizumab demonstrates a dose-dependent decrease in FLT-PET standardized uptake value which correlates with clinical response. SECONDARY OBJECTIVES: I. To determine the relationship between FLT-PET and markers of angiogenesis and drug activity in tumor biopsy, along with surrogate peripheral blood markers of target inhibition and drug activity. OUTLINE: Patients undergo fluorine F-18 fluorothymidine PET at baseline, at day 6-8 of course 1, day 20 of course 2, and prior to day 1 of course 3.